Takeda shares have not been able to overcome overhead resistance and are likely to test their October 2022 lows. See why we continue to rate TAK stock a hold.

In terms of year-over-year revenue growth, Takeda observed a 5.87% increase, while JNJ and BMY had an 11.02% and 0.68% decrease respectively. On the other hand, ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of ...

ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...

We recently compiled a list of the 10 Best Japanese Stocks To Buy Now. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the ...

Plasma-Derived Therapies Immunology, with 502.4 billion yen in reported revenue, delivered outstanding growth of +18% on a CER basis. Growth was driven by higher ...

Takeda Pharmaceutical Co (JP:4502) has released an update. Takeda Pharmaceutical Co. reported a strong financial performance for the six months ending September 30, 2024, with a significant ...

Plasma collection has recently returned to pre-pandemic levels at Takeda, and the company expects about 10% to 20% donation volume growth year over year in its fiscal year that ends in March 2023.

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) is the largest Japanese pharmaceutical company and holds a leading position in the global immunoglobulins market. In recent months, the company's share ...

Takeda Pharmaceutical Company ( (TAK)) has released its Q2 earnings. Here is a breakdown of the information Takeda Pharmaceutical Company presented to its investors. Takeda Pharmaceutical Company ...

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of ...